Clinical Trials
Research Update
Gene Therapy for Advanced Parkinson's A Phase II study at UCSF is testing AAV2-GDNF, a gene therapy delivered directly to the putamen. The randomized, double-blind trial aims to evaluate safety and efficacy in adults ages 45–75 with moderate Parkinson's disease. https://clinicaltrials.ucsf.edu/trial/NCT06285643 Stem Cell Transplant Trial UCSD is recruiting participants ages 40–75 for a Phase I/II trial transplanting human induced pluripotent stem cell-derived dopaminergic progenitors into the corpus striatum. The study evaluates safety and efficacy of this novel cell replacement approach. https://clinicaltrials.ucsd.edu/trial/NCT06482268 Prasinezumab in Early-Stage Parkinson's UCSF is conducting an intravenous prasinezumab trial in participants ages 50–85 with early-stage PD on stable levodopa monotherapy. The Phase IIb study evaluates efficacy, safety, and pharmacokinetics of this alpha-synuclein-targeting antibody. https://clinicaltrials.ucsf.edu/trial/NCT07174310 Exercise and Cognitive Function A UCSF home-based virtual study is evaluating combined high-intensity endurance and resistance training in people ages 40–80 with PD, measuring effects on cognition and exercise-related biomarkers. https://clinicaltrials.ucsf.edu/trial/NCT05720468
Breakthrough Treatments
Research Update
New Subcutaneous Infusion Approved for Advanced PD In January 2026, the FDA approved Vyalev (foscarbidopa/foslevodopa), a continuous subcutaneous infusion delivering two established Parkinson's medications through a small pump. The therapy provides steady medication levels with less invasiveness than previous options, offering a new treatment pathway for advanced PD patients. https://www.abnewswire.com/pressreleases/parkinsons-disease-pipeline-2026-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca-prevail-therapeutics_800298.html Disease-Modifying Drug Advances to Phase III Prasinezumab, a Roche drug targeting toxic alpha-synuclein proteins that drive dopamine neuron death, has moved into Phase III clinical trials. If successful, it could become one of the first disease-modifying treatments available for Parkinson's, potentially slowing or halting disease progression rather than just managing symptoms. https://www.michaeljfox.org/news/drug-potential-slow-or-stop-parkinsons-moves-next-phase-clinical-testing Ambroxol Shows Promise for Parkinson's Dementia The common European cough medication ambroxol demonstrated symptom stabilization and reduced brain-damage markers in Parkinson's dementia patients over 12 months, while placebo patients worsened. Those with high-risk genetic markers showed the most benefit. https://www.sciencedaily.com/news/health_medicine/parkinson's_disease/
Lifestyle Interventions
Research Update
Lifestyle Bundle Improves PD Outcomes The SENSS study is a 12-month randomized controlled trial at Radboud University Medical Center testing an integrated lifestyle approach combining stress management, exercise, nutrition, sleep optimization, and self-management coaching for 256 people with Parkinson's disease. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2026.1752073/full Exercise Significantly Improves Sleep and Motor Function A systematic review and meta-analysis of 62 randomized controlled trials with 3,274 participants found that exercise interventions led to significant improvements in sleep quality, motor capability, balance, gait performance, and overall quality of life in PD patients. https://pmc.ncbi.nlm.nih.gov/articles/PMC12654900/ Exercise Restores Sleep Architecture in PD Research shows both high and low-intensity aerobic, resistance, and balance-coordination exercises improve sleep in Parkinson's patients. Exercise increases brain-derived neurotrophic factors (BDNF) and promotes toxin clearance including alpha-synuclein during sleep. https://link.springer.com/article/10.1186/s12883-024-03548-9
Emerging Research
Research Update
Mitochondrial Dysfunction as Key Target A 2026 review in Tissue Barriers highlights mitochondrial dysfunction and oxidative stress as central to PD pathophysiology. Emerging biomarkers include lipid peroxidation and mitochondrial DNA damage measurements. Promising strategies include mitochondria-targeted antioxidants like MitoQ, PINK1-based gene therapy, and ketogenic diet approaches. https://pubmed.ncbi.nlm.nih.gov/40813952/ T Cells Identified as Early Parkinson's Biomarker Researchers discovered misbehaving T cells surge long before Parkinson's symptoms appear, zeroing in on vulnerable brain proteins. This early immune activity could serve as both an early warning signal and a therapeutic target for stopping disease progression before symptoms manifest. https://www.sciencedaily.com/news/health_medicine/parkinson's_disease/ Biomarker-Based Diagnosis Framework Nature reviews the progress toward a validated biomarker-based diagnostic framework for Parkinson's disease, addressing the limitations of current clinical diagnostic criteria. Blood-based and CSF biomarkers are showing promise for earlier and more accurate diagnosis. https://www.nature.com/articles/s41582-026-01185-z Generated daily from public research databases. For informational purposes only — not medical advice.
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.